Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Product Briefs: Abbott Glucose Monitor, Boston Sci EP Mapping System Gain 510(k)s

This article was originally published in The Gray Sheet

Executive Summary

Abbott’s FreeStyle Precision Pro blood glucose and beta-ketone monitoring system and Boston Scientific’s Rhythmia EP-mapping system earned 510(k) clearances. Also, Boston Sci’s OptiCross imaging catheter gained regulatory clearance in three countries. More new product news.

You may also be interested in...



Bard EP Deal Latest In Boston Scientific’s M&A Revival, Bolsters CRM Business

Boston Scientific’s recent acquisition of Bard Electrophysiology marks the tenth notable acquisition that it has made since 2010. Four of those deals come in cardiac rhythm management, including EP, which is among the fastest-growing device sectors and one that company executives see as a major contributor to future growth.

Bard EP Deal Latest In Boston Scientific’s M&A Revival, Bolsters CRM Business

Boston Scientific’s recent acquisition of Bard Electrophysiology marks the tenth notable acquisition that it has made since 2010. Four of those deals come in cardiac rhythm management, including EP, which is among the fastest-growing device sectors and one that company executives see as a major contributor to future growth.

New Products In Brief

Abbott earns approval in Japan for Xience Xpedition everolimus-eluting stent. Zimmer will distribute SpineCraft’s APEX system. More new product news.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032282

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel